U.S. pharma huge copyright scrapped two experimental weight loss drugs very last calendar year—a as soon as-everyday tablet, lotiglipron, due to elevated liver enzymes along with a two times-day-to-day tablet, danuglipron, as a consequence of potent side effects—but CEO Albert Bourla has said the company is determined to “Enjoy and earn” in